Loading...


Speakers
Home >  Overview >  Speakers

Panellist

Dr. Zheng Yuewen

Vice Chairman, All-China Federation of Industry and Commerce

 

Zheng Yuewen, Board Chairman of Creat Group Co Ltd, was born in January 1962. He graduated from the Jiangxi University of Finance and Economics in 1985 and received a PhD in Finance from the Dongbei University of Finance and Economics in 1999.

Serving as a member of the 10th, 11th, 12th and 13th CPPCC National Committee since 2003, Zheng was elected as a Standing Committee member of the 13th CPPCC in March 2018. He has also been serving as a specially invited supervisor of the Ministry of Supervision since December 2010.

Zheng served as Vice Chairman of the 9th All-China Federation of Industry and Commerce (ACFIC) from 2002 to 2007, and Vice Chairman of the 10th All-China General Chamber of Industry & Commerce from 2007 to 2012. He was elected as Vice Chairman of the 12th ACFIC in November 2017.

Having served as Chairman of the China International Chamber of Commerce for the Private Sector since November 2011, Zheng also served as Chairman of the China-Africa Business Council (CABC) from March 2012 to December 2017, and has been serving as Chief Supervisor of CABC since December 2017, as well as Chairman of the Jiangxi Businessmen’s Alliance in China since November 2011.

Creat Group Co Ltd, established in 1992 by Zheng, is headquartered in Beijing. With more than 20 years’ development, the company has become a large-scale private enterprise group based on industry and develops industrial management and capital management together. The enterprise covers industries like medicine, manufacturing, mining, agriculture, etc, and has owned six listed companies at home and abroad successively. Currently, biological medicine is the priority industry for Creat Group Co Ltd, and its Shanghai RAAS Blood Products Co Ltd is the best brand among Chinese blood products. Since listed in 2008 and through mergers and acquisitions, Shanghai RAAS has become the leading enterprise of the Chinese biopharmaceutical industry and the largest blood products enterprise


This material/event is funded by the Professional Services Advancement Support Scheme of the Government of the Hong Kong Special Administrative Region.
Any opinions, findings, conclusions or recommendations expressed in this material/any event organised under this project do not reflect the views of
the Government of the Hong Kong Special Administrative Region or the Vetting Committee of the Professional Services Advancement Support Scheme.